Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

Frank C. Arnett, Steven M. Edworthy, D. Blöch et al. · Arthritis & Rheumatism · 1988 · 19.9K citations

Medicine, Clinical Sciences, Internal Medicine +12

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

René de Waal Malefyt, John B.A.G. Haanen, Hergen Spits et al. · The Journal of Experimental Medicine · 1991 · 1.9K citations · Full text

Life Sciences, Cell Biology, Immunology +15

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden et al. · Arthritis & Rheumatism · 1998 · 1.6K citations

Pharmacy, Clinical Sciences, Pharmacotherapy +17

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

Zuoning Han, David L. Boyle, Lufen Chang et al. · Journal of Clinical Investigation · 2001 · 775 citations · Full text

Life Sciences, Immunology, Molecular Biology +13

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

Josef S Smolen, Joachim R. Kalden, David L. Scott et al. · The Lancet · 1999 · 773 citations

Medicine, Pharmacology, Pharmacotherapy +10